Literature DB >> 7258300

Effects of heparin on platelet aggregation and release and thromboxane A2 production.

S F Mohammad, W H Anderson, J B Smith, H Y Chuang, R G Mason.   

Abstract

Heparin, when added to citrated platelet-rich plasma (PRP), caused potentiation of platelet aggregation and the release reaction induced by the aggregating agents adenosine diphosphate (ADP), arachidonic acid, collagen, and epinephrine. At low concentrations (4.7 x 10(-5) M) arachidonic acid failed to cause aggregation of platelets in citrated PRP. However, in the presence of heparin, the same concentration of arachidonic acid caused aggregation. Examination of PRP for the presence of thromboxane A2 (TxA2) by use of a bioassay revealed that heparin also stimulated release of TxA2. This finding indicated that platelets released more TxA2 when they were challenged by low concentrations of arachidonic acid in the presence of heparin than in its absence. Platelets were labeled with 3H-arachidonic acid and 14C-serotonin, and attempts were made to determine whether heparin stimulated the platelet release reaction first with subsequent increased production of TxA2, or alternatively, whether heparin stimulated TxA2 production first with subsequent enhancement of the release reaction. In view of the demonstrated simultaneous release of 14C-serotonin and 3H-arachidonic acid metabolites, it appeared that either release of 14C and 3H occurs concurrently or, even if one of these events is dependent on the other, both events take place in rapid succession. Timed sequential studies revealed that in the presence of arachidonic acid, the addition of heparin hastened the apparently simultaneous release of both 14C and 3H.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7258300      PMCID: PMC1903756     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

Review 1.  Effect of heparin on platelet function.

Authors:  M B Zucker
Journal:  Thromb Diath Haemorrh       Date:  1975-02-28

2.  Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs.

Authors:  P J Piper; J R Vane
Journal:  Nature       Date:  1969-07-05       Impact factor: 49.962

3.  Heparin effects on plasma lysolecithin formation and platelet aggregation.

Authors:  E M Besterman; M P Gillett
Journal:  Atherosclerosis       Date:  1973 May-Jun       Impact factor: 5.162

4.  Physiologic role of prostaglandins of the E(PGE), F(PGF) and AB(PGAB) groups. Estimation by radioimmunoassay in unextracted human plasma.

Authors:  W Jubiz; J Frailey; C Child; K Bartholomew
Journal:  Prostaglandins       Date:  1972-12

5.  Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations.

Authors:  G R Rhodes; R H Dixon; D Silver
Journal:  Surg Gynecol Obstet       Date:  1973-03

6.  A modification of the technique for 51Cr-labelling of blood platelets giving increased circulating platelet radioactivity.

Authors:  A F Abrahamsen
Journal:  Scand J Haematol       Date:  1968

7.  Significance of phospholipase A for prostaglandin formation.

Authors:  H Kunze; W Vogt
Journal:  Ann N Y Acad Sci       Date:  1971-04-30       Impact factor: 5.691

8.  On the mechanism of platelet aggregation induced by heparin, protamine and polybrene.

Authors:  C Eika
Journal:  Scand J Haematol       Date:  1972

9.  Effect of heparin on platelet economy in dogs.

Authors:  H C Rowsell; M F Glynn; J F Mustard; E A Murphy
Journal:  Am J Physiol       Date:  1967-10

10.  Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods.

Authors:  J C Fratantoni; R Pollet; H R Gralnick
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

View more
  8 in total

1.  Effect of dexamethasone on in vivo prostanoid production in the rabbit.

Authors:  A Náray-Fejes-Tóth; G Fejes-Tóth; C Fischer; J C Frölich
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

2.  [Thromboxane concentrations in the arterial blood of cigarette smokers].

Authors:  F J Krause
Journal:  Klin Wochenschr       Date:  1986-07-15

3.  Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat.

Authors:  F De Clerck; Y Somers; L Van Gorp; B Xhonneux
Journal:  Agents Actions       Date:  1983-02

4.  Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.

Authors:  D P Mikhailidis; M A Barradas; A M Mikhailidis; H Magnani; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

5.  Heparin uncouples alpha 2-adrenoceptors from the Gi-protein in membranes of human platelets.

Authors:  B Willuweit; K Aktories
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

6.  Extravasated platelet aggregation in liver zone 3 may correlate with the progression of sinusoidal obstruction syndrome following living donor liver transplantation: A case report.

Authors:  Shinichi Nakanuma; Tomoharu Miyashita; Hironori Hayashi; Hidehiro Tajima; Hiroyuki Takamura; Tomoya Tsukada; Koichi Okamoto; Seisho Sakai; Isamu Makino; Jun Kinoshita; Keishi Nakamura; Katsunobu Oyama; Masafumi Inokuchi; Hisatoshi Nakagawara; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Exp Ther Med       Date:  2015-02-02       Impact factor: 2.447

7.  The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target.

Authors:  Bartlomiej Kalaska; Joanna Miklosz; Kamil Kamiński; Bogdan Musielak; Shin-Ichi Yusa; Dariusz Pawlak; Maria Nowakowska; Krzysztof Szczubiałka; Andrzej Mogielnicki
Journal:  RSC Adv       Date:  2019-01-23       Impact factor: 4.036

8.  Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.

Authors:  Eugene Jeong; Scott D Nelson; Yu Su; Bradley Malin; Lang Li; You Chen
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.